Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach

Riffat Mehboob, Fridoon Jawad Ahmad, Ahad Qayyum, Muhammad Asim Rana, Muhammad Akram Tariq, Javed Akram
doi: https://doi.org/10.1101/2020.08.01.20166678

Article Information

doi 
https://doi.org/10.1101/2020.08.01.20166678
History 
  • August 4, 2020.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Riffat Mehboob1,*,
  2. Fridoon Jawad Ahmad2,
  3. Ahad Qayyum3,
  4. Muhammad Asim Rana3,
  5. Muhammad Akram Tariq4 and
  6. Javed Akram2
  1. 1Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
  2. 2Deparmtnet of Physiology, University of Health Sciences, Lahore, Pakistan
  3. 3Bahria International Hospital, Lahore, Pakistan
  4. 4Higher Education Department Punjab, Lahore, Pakistan
  1. ↵*Corresponding author details:
    Prof. Dr. Riffat Mehboob, Research Unit, Faculty of Allied Health Sciences, The University of Lahore Lahore, Pakistan, mehboob.riffat{at}gmail.com
Back to top
Posted August 04, 2020.
Download PDF
Data/Code
Email
Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach
Riffat Mehboob, Fridoon Jawad Ahmad, Ahad Qayyum, Muhammad Asim Rana, Muhammad Akram Tariq, Javed Akram
medRxiv 2020.08.01.20166678; doi: https://doi.org/10.1101/2020.08.01.20166678
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area